GB201615910D0 - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- GB201615910D0 GB201615910D0 GBGB1615910.5A GB201615910A GB201615910D0 GB 201615910 D0 GB201615910 D0 GB 201615910D0 GB 201615910 A GB201615910 A GB 201615910A GB 201615910 D0 GB201615910 D0 GB 201615910D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1615910.5A GB2554089A (en) | 2016-09-19 | 2016-09-19 | Pharmaceutical composition |
| CA3037080A CA3037080C (en) | 2016-09-19 | 2017-09-18 | Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis) |
| BR112019005080-9A BR112019005080B1 (en) | 2016-09-19 | 2017-09-18 | PHARMACEUTICAL COMPOSITION, METERED-DOSE INHALER, AND METHODS FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION, FOR INCREASING THE STABILIZATION TIME OF A PHARMACEUTICAL COMPOSITION AND FOR IMPROVING THE AEROSOLIZATION PERFORMANCE OF A PHARMACEUTICAL COMPOSITION |
| CN202310227306.XA CN116270640A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| JP2019515269A JP6781830B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| CN201780057065.1A CN109715160A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| PCT/GB2017/052757 WO2018051128A1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| ES21183138T ES2949975T3 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising indacaterol |
| EP21183138.3A EP3909582B1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising indacaterol |
| CN202110262649.0A CN113288869A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| MX2019003105A MX387725B (en) | 2016-09-19 | 2017-09-18 | PHARMACEUTICAL COMPOSITION. |
| EP17777634.1A EP3515441B1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising indacaterol |
| AU2017328905A AU2017328905C1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| ES17777634T ES2891579T3 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| US16/334,151 US11260052B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| MX2021010022A MX2021010022A (en) | 2016-09-19 | 2019-03-15 | Pharmaceutical composition. |
| AU2020202580A AU2020202580B2 (en) | 2016-09-19 | 2020-04-16 | Pharmaceutical composition |
| JP2020140692A JP6972256B2 (en) | 2016-09-19 | 2020-08-24 | Pharmaceutical composition |
| US17/577,824 US20220133709A1 (en) | 2016-09-19 | 2022-01-18 | Pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1615910.5A GB2554089A (en) | 2016-09-19 | 2016-09-19 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201615910D0 true GB201615910D0 (en) | 2016-11-02 |
| GB2554089A GB2554089A (en) | 2018-03-28 |
Family
ID=57288853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1615910.5A Withdrawn GB2554089A (en) | 2016-09-19 | 2016-09-19 | Pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2554089A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112051346A (en) * | 2020-09-24 | 2020-12-08 | 珠海瑞思普利生物制药有限公司 | HPLC method for simultaneously determining content of indacaterol and glycopyrronium bromide |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2584686A (en) * | 2019-06-11 | 2020-12-16 | Mexichem Fluor Sa De Cv | Methods |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014505717A (en) * | 2011-02-17 | 2014-03-06 | シプラ・リミテッド | Pharmaceutical composition |
| GB201306984D0 (en) * | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
-
2016
- 2016-09-19 GB GB1615910.5A patent/GB2554089A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112051346A (en) * | 2020-09-24 | 2020-12-08 | 珠海瑞思普利生物制药有限公司 | HPLC method for simultaneously determining content of indacaterol and glycopyrronium bromide |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2554089A (en) | 2018-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265260B (en) | Pharmaceutical composition | |
| IL265360B (en) | Pharmaceutical composition | |
| IL262654A (en) | Pharmaceutical composition | |
| IL271986B1 (en) | Pharmaceutical composition | |
| IL265349A (en) | Pharmaceutical composition | |
| GB201712159D0 (en) | Pharmaceutical composition | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| HUE068810T2 (en) | Pharmaceutical composition | |
| IL272419A (en) | Pharmaceutical composition | |
| GB201719447D0 (en) | Pharmaceutical composition | |
| IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
| PL3646867T3 (en) | Pharmaceutical composition | |
| PL3454838T3 (en) | Pharmaceutical composition | |
| GB201615917D0 (en) | Pharmaceutical composition | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| GB201615914D0 (en) | Pharmaceutical composition | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| IL263999A (en) | Pharmaceutical compositions | |
| GB201615910D0 (en) | Pharmaceutical composition | |
| IL265436B (en) | Pharmaceutical composition | |
| ZA201705782B (en) | Pharmaceutical compositions | |
| PL3424500T3 (en) | Pharmaceutical composition comprising famitinib | |
| GB201620519D0 (en) | Pharmaceutical composition | |
| IL265428A (en) | Pharmaceutical composition | |
| PT3476391T (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |